Lewy Pathology is Not the First Sign of Degeneration in Vulnerable Neurons in Parkinson Disease
Authors
Affiliations
Objective: To determine whether evidence of neuronal dysfunction or demise preceded deposition of Lewy pathology in vulnerable neurons in Parkinson disease (PD).
Methods: We examined the extent of nigral dysfunction and degeneration among 63 normal, incidental Lewy body disease (ILBD), and PD cases based on tyrosine hydroxylase (TH) immunoreactivity and neuron densities, respectively. The relationship between these markers and Lewy pathology (LP) burden in the substantia nigra (SN) and Braak PD stage was assessed.
Results: Compared with normal subjects, ILBD cases displayed a significantly higher percentage of TH-negative cells and lower neuronal densities in the SN as early as Braak PD stages 1 and 2, before LP deposition in the nigrostriatal system. ILBD nigral neuron densities were intermediate between normal subjects and PD cases, and TH-negative percentages were higher in ILBD than either normal or PD cases. Furthermore, neuron density and neuronal dysfunction levels remained relatively constant across Braak PD stages in ILBD.
Conclusions: These results suggest that significant neurodegeneration and cellular dysfunction precede LP in the SN, challenging the pathogenic role of LP in PD and the assumption that ILBD always represents preclinical PD.
Current insights and assumptions on α-synuclein in Lewy body disease.
Leak R, Clark R, Abbas M, Xu F, Brodsky J, Chen J Acta Neuropathol. 2024; 148(1):18.
PMID: 39141121 PMC: 11324801. DOI: 10.1007/s00401-024-02781-3.
Selective dopaminergic neurotoxicity modulated by inherent cell-type specific neurobiology.
Currim F, Tanwar R, Brown-Leung J, Paranjape N, Liu J, Sanders L Neurotoxicology. 2024; 103:266-287.
PMID: 38964509 PMC: 11288778. DOI: 10.1016/j.neuro.2024.06.016.
Abioye A, Akintade D, Mitchell J, Olorode S, Adejare A Pharmaceutics. 2024; 16(5).
PMID: 38794271 PMC: 11124533. DOI: 10.3390/pharmaceutics16050609.
The role of the brain renin-angiotensin system in Parkinson´s disease.
Labandeira-Garcia J, Labandeira C, Guerra M, Rodriguez-Perez A Transl Neurodegener. 2024; 13(1):22.
PMID: 38622720 PMC: 11017622. DOI: 10.1186/s40035-024-00410-3.
Lage L, Rodriguez-Perez A, Villar-Cheda B, Labandeira-Garcia J, Dominguez-Meijide A NPJ Parkinsons Dis. 2024; 10(1):37.
PMID: 38368444 PMC: 10874459. DOI: 10.1038/s41531-024-00650-0.